RSS | Login | Register

TAMIFLU

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare TAMIFLU to:

TAMIFLU (Oseltamivir) 30mg, 45mg, 75mg capsules by Roche Laboratories

Generic Name for TAMIFLU

Oseltamivir (as phosphate) 30mg, 45mg, 75mg; caps.

Legal Classification:

Pharmacological Class for TAMIFLU

Neuraminidase inhibitor.

Manufacturer of TAMIFLU

Roche Laboratories

Indications for TAMIFLU

Treatment of uncomplicated acute illness due to influenza infection in patients ≥1year of age who have been symptomatic for ≤2days. Prophylaxis of influenza in patients ≥1year of age.

Adult dose for TAMIFLU

Start within 2 days of symptom onset or exposure. ≥13yrs: Treatment: 75mg twice daily for 5 days; CrCl 10–30mL/min: 75mg once daily for 5 days. Prophylaxis: after close contact with infected individual: 75mg once daily for at least 10 days; during community outbreak: 75mg once daily for up to 6 weeks; CrCl 10–30mL/min: 75mg every other day or 30mg once daily.

Children's dosing for TAMIFLU

<1yr: not recommended. 1–12yrs: Start within 2 days of symptom onset. Treatment: Treat for 5 days. ≤15kg: 30mg twice daily; 16–23kg: 45mg twice daily; 24–40kg: 60mg twice daily; >40kg: 75mg twice daily. Prophylaxis: Treat for 10 days. ≤15kg: 30mg once daily; 16–23kg: 45mg once daily; 24–40kg: 60mg once daily; >40kg: 75mg once daily.

Also:

TAMIFLU ORAL SUSPENSION

Warnings/Precautions for TAMIFLU

Not a substitute for influenza vaccination. Hepatic impairment. Chronic cardiac or respiratory disease. Immunocompromised. Monitor for signs of abnormal behavior (esp. in children). Pregnancy (Cat.C). Nursing mothers.

Interactions for TAMIFLU

Do not administer live attenuated influenza vaccine within 2 weeks prior or 48 hrs after treatment.

Adverse Reactions for TAMIFLU

GI upset, bronchitis, headache, insomnia, vertigo, fatigue; possible neuropsychiatric events (eg, hallucinations, delirium, abnormal behavior).

How is TAMIFLU supplied?

Caps—10
Susp—25mL (w. oral dispenser)

Related Disease:

Influenza~antivirals

Abbott RealTime HBV test approved

September 02, 2010

Abbott announced that the FDA has approved its RealTime HBV assay for measuring the amount of hepatitis B virus (HBV) in human plasma or serum from individuals chronically infected with HBV.

Longer use of Valcyte for renal transplant patients approved

August 11, 2010

The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.

Phase 3 study of boceprevir for the treatment of HCV

August 05, 2010

Merck announced the completion and results of its two Phase 3 studies for boceprevir for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.

Afluria labeling updated to include fever and febrile seizure risk

August 02, 2010

The Prescribing Information for Afluria (trivalent, inactivated, "split virus" influenza vaccine [Types A and B], from CSL Biotherapies) has been updated to inform healthcare professionals of an increased incidence of fever and febrile seizure among young children in Australia, mainly those <5years of age.

Fluzone available for 2010-2011 influenza season

July 30, 2010

Sanofi Pasteur announced that it has begun shipping the 2010-2011 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).